



Log In



Submit



E-Alerts



Subscribe

[OpenAthens/Shibboleth »](#)

MENU

[Journal of Clinical Oncology](#) > [List of Issues](#) >
[Volume 39, Issue 23](#) >



Article Tools

ORIGINAL REPORTS | Thoracic Oncology

Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis



Francesco Passiglia, MD¹; Michela Cinquini, BSc²; Luca Bertolaccini, MD³; Marzia Del Re, MD⁴; Francesco Facchinetti, MD⁵; Roberto Ferrara, MD⁶; ...

[Show More](#)

*F.P. and M.C. contributed equally to this work.

Abstract Full Text PDF Figures and Tables

ABSTRACT

PURPOSE

This meta-analysis aims to combine and analyze randomized clinical trials comparing computed tomography lung screening (CTLS) versus either no screening (NS) or chest x-ray (CXR) in subjects with

This site uses tracking technologies through the use of permanent cookies and web beacons/pixel tags. By default, cookies are set to "Allow all cookies." If you continue to use this site, then you acknowledge our use of cookies. For additional information, including on how to change your cookie settings, please visit "Cookies Settings" and review our [Privacy Policy](#) and [Terms of Use](#).

OPTIONS & TOOLS

[Export Citation](#)
[Track Citation](#)
[Add To Favorites](#)
[Purchase](#)
[Rights & Permissions](#)


ADVERTISEMENT

COMPANION ARTICLES

No companion articles

ARTICLE CITATION

DOI: 10.1200/JCO.20.02574
Journal of Clinical Oncology
 39, no. 23 (August 10, 2021)
 2574-2585.

Published online June 02, 2021.

PMID: [34236916](#)

WE RECOMMEND

ADVERTISEMENT

ADVERTISEMENT

[> Cookie Settings](#)
[✓ Accept Cookies](#)

Meta-Analyses guidelines. Subgroup analyses by comparator (NS or CXR) were performed. Pooled risk ratio (RR) and relative 95% CIs were calculated for dichotomous outcomes. The certainty of the evidence was assessed using the GRADE approach.

RESULTS

Nine eligible trials (88,497 patients) were included. Pooled analysis showed that CTLS is associated with: a significant reduction of lung cancer-related mortality (overall RR, 0.87; 95% CI, 0.78 to 0.98; NS RR, 0.80; 95% CI, 0.69 to 0.92); a significant increase of early-stage tumors diagnosis (overall RR, 2.84; 95% CI 1.76 to 4.58; NS RR, 3.33; 95% CI, 2.27 to 4.89; CXR RR, 1.52; 95% CI, 1.04 to 2.23); a significant decrease of late-stage tumors diagnosis (overall RR, 0.75; 95% CI, 0.68 to 0.83; NS RR, 0.67; 95% CI, 0.56 to 0.80); a significant increase of resectability rate (NS RR, 2.57; 95% CI, 1.76 to 3.74); a nonsignificant reduction of all-cause mortality (overall RR, 0.99; 95% CI, 0.94 to 1.05); and a significant increase of overdiagnosis rate (NS, 38%; 95% CI, 14 to 63). The analysis of lung cancer-related mortality by sex revealed nonsignificant differences between men and women ($P = .21$; I-squared = 33.6%).

CONCLUSION

Despite there still being uncertainty about overdiagnosis estimate, this meta-analysis suggested that the CTLS benefits outweigh harms, in subjects with cigarette smoking history, ultimately supporting the systematic implementation of lung cancer screening worldwide.

© 2021 by American Society of Clinical Oncology

CONTEXT

Key Objective

This meta-analysis provides an updated estimation of the benefits and harms associated with computed tomography lung screening (CTLS) in subjects with cigarette smoking history, which may serve as scientific support for evidence-based guidelines.

Knowledge Generated

CTLS was associated with a significant 20% reduction of

This site uses tracking technologies through the use of permanent cookies and web beacons/pixel tags. By default, cookies are set to "Allow all cookies." If you continue to use this site, then you acknowledge our use of cookies. For additional information, including on how to change your cookie settings, please visit "Cookies Settings" and review our [Privacy Policy](#) and [Terms of Use](#).

Mortality

Gary M. Strauss, J Clin Oncol, 2016

Hyperfractionated or Accelerated Radiotherapy in Lung Cancer: An Individual Patient Data Meta-Analysis

Audrey Mauguén et al., J Clin Oncol, 2012

Cannabis Smoking and Risk of Cancer: A Meta-Analysis of Observational Studies

S. Park et al., JCO Global Oncology, 2018

Overcoming Perceived Hurdles in Lung Cancer Screening: The Low Risk of Complications of Image-Guided Transthoracic Needle Biopsy

Jyoti D. Patel, JCO Oncology Practice, 2015

Surgeon General report identifies more health hazards from smoking

Healio

Thrombolytics for venous thromboembolic events: a systematic review with meta-analysis

Izcovich et al., Blood Advances, 2020

Benefits and Harms of CT Screening for Lung Cancer: A Systematic Review

Peter B. Bach et al., JAMA Oncology

Lung cancer screening significantly reduces mortality, meta-analysis shows

Healio

One Codex, Transnetyx Collaborate on Microbiome Sequencing and Analysis Services | Genomeweb staff reporter, GenomeWeb

Powered by
TREND MD

I consent to the use of
Google Analytics and

> [Cookie Settings](#)

✓ [Accept Cookies](#)

supporting the systematic implementation of lung cancer screening worldwide.

Your Access Options

Log In

If you have an individual subscription to this content, or if you have purchased this content through *Pay Per Article* within the past 24 hours, you can gain access by logging in with your username and password here:

[Log In / Register](#)

[Forgotten your password?](#)

[Register](#)

[OpenAthens](#)

[Log In Via Your Institution](#)

Subscribe

[Subscribe to this Journal](#)

[Renew Your Subscription](#)

To purchase the **JCO Legacy Archive**, call Customer Service at 888-282-2552 or 703-299-0158.

Purchase this Article

Access to articles in print or PDF format is available without a subscription.

[Purchase](#)

AUTHOR CONTRIBUTIONS

Conception and design: Francesco Passiglia, Michela Cinquini, Luca Bertolaccini, Roberto Ferrara, Anna R. Larici, Jessica Menis, Silvia Novello

Provision of study materials or patients: Luca Bertolaccini, Umberto Malapelle

Collection and assembly of data: Francesco Passiglia, Michela Cinquini, Luca Bertolaccini, Marzia Del Re, Tindara Franchina, Jessica Menis, Sara Pilotto, Sara Ramella, Rocco Trisolini, Silvia Novello

Data analysis and interpretation: Francesco Passiglia, Michela Cinquini, Luca Bertolaccini, Marzia Del Re, Francesco Facchinetti

This site uses tracking technologies through the use of permanent cookies and web beacons/pixel tags. By default, cookies are set to “Allow all cookies.” If you continue to use this site, then you acknowledge our use of cookies. For additional information, including on how to change your cookie settings, please visit “Cookies Settings” and review our [Privacy Policy](#) and [Terms of Use](#).

› [Cookie Settings](#)

✓ [Accept Cookies](#)

compensated unless otherwise noted. Relationships are self-reported unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians ([Open Payments](#)).

Francesco Passiglia

Consulting or Advisory Role: AstraZeneca, MSD Oncology, Amgen

Travel, Accommodations, Expenses: MSD Oncology, Roche

Marzia Del Re

Consulting or Advisory Role: Sanofi, Celgene, Janssen-Cilag, Ipsen, Roche Molecular Diagnostics

Speakers' Bureau: Sanofi, Pfizer, Novartis, Janssen-Cilag, Ipsen, AstraZeneca, Astellas Pharma

Francesco Facchinetti

Other Relationship: Roche, Bristol Myers Squibb

Roberto Ferrara

Consulting or Advisory Role: Merck Sharp & Dohme

Tindara Franchina

Honoraria: Novartis, AstraZeneca

Consulting or Advisory Role: Boehringer Ingelheim, Merck Sharp & Dohme

Anna R. Larici

Speakers' Bureau: Boehringer Ingelheim

Umberto Malapelle

Consulting or Advisory Role: Boehringer Ingelheim, Roche, Merck Sharp & Dohme, Amgen, Thermo Fisher Scientific, Lilly, Diaceutics, GlaxoSmithKline, Merck, AstraZeneca

Speakers' Bureau: Boehringer Ingelheim, AstraZeneca, Roche, Merck Sharp & Dohme, Amgen, Merck, Thermo Fisher Scientific, Lilly, Diaceutics, GlaxoSmithKline

Jessica Menis

Consulting or Advisory Role: MSD Oncology, Roche/Genentech, Boehringer Ingelheim, AstraZeneca, Bristol Myers Squibb/Pfizer

Speakers' Bureau: AstraZeneca/MedImmune, Bristol Myers

This site uses tracking technologies through the use of permanent cookies and web beacons/pixel tags. By default, cookies are set to "Allow all cookies." If you continue to use this site, then you acknowledge our use of cookies. For additional information, including on how to change your cookie settings, please visit "Cookies Settings" and review our [Privacy Policy](#) and [Terms of Use](#) .

> [Cookie Settings](#)

✓ [Accept Cookies](#)

Myers Squibb

Sara Pilotto

Honoraria: Bristol Myers Squibb, Boehringer Ingelheim, AstraZeneca

Speakers' Bureau: Bristol Myers Squibb, Boehringer Ingelheim, Roche, MSD Oncology, AstraZeneca

Research Funding: AstraZeneca

Travel, Accommodations, Expenses: Bristol Myers Squibb, Roche, AstraZeneca

Sara Ramella

Honoraria: AstraZeneca, Amgen

Consulting or Advisory Role: AstraZeneca, Roche, Ipsen

Rocco Trisolini

Honoraria: Pentax Medical Devices

Silvia Novello

Consulting or Advisory Role: Sanofi

Speakers' Bureau: AstraZeneca, Merck Sharp & Dohme, Bristol Myers Squibb, Roche, Pfizer, Lilly, Takeda, AbbVie, Boehringer Ingelheim, Bayer, Amgen, Beigene

No other potential conflicts of interest were reported.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.

- [Personal login](#)
- [Institutional Login](#)
- [OpenAthens](#)
- [Restore content access](#)

This functionality works only for purchases made as a guest



QUICK LINKS

Content

Newest Articles
Archive
Meeting Abstracts

Journal Information

Resources

Authors
Reviewers
Subscribers
Institutions
Advertisers



ASCO FAMILY OF SITES

Journals

Journal of Clinical
Oncology
JCO Oncology Practice
JCO Global Oncology
ICO Clinical Cancer

Education

ASCO eLearning
ASCO Meetings
Cancer.Net

Other Sites

This site uses tracking technologies through the use of permanent cookies and web beacons/pixel tags. By default, cookies are set to "Allow all cookies." If you continue to use this site, then you acknowledge our use of cookies. For additional information, including on how to change your cookie settings, please visit "Cookies Settings" and review our [Privacy Policy](#) and [Terms of Use](#).

> [Cookie Settings](#)

✓ [Accept Cookies](#)

This site uses tracking technologies through the use of permanent cookies and web beacons/pixel tags. By default, cookies are set to “Allow all cookies.” If you continue to use this site, then you acknowledge our use of cookies. For additional information, including on how to change your cookie settings, please visit “Cookies Settings” and review our [Privacy Policy](#) and [Terms of Use](#).

[Cookie Settings](#)

✓ [Accept Cookies](#)